Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis

Juan S. Lasa, Pablo A. Olivera, Stefanos Bonovas, Silvio Danese and Laurent Peyrin-Biroulet ()
Additional contact information
Juan S. Lasa: Centro de Educación Médica e Investigación Clínica (CEMIC)
Pablo A. Olivera: Centro de Educación Médica e Investigación Clínica (CEMIC)
Stefanos Bonovas: Humanitas University
Silvio Danese: Humanitas University
Laurent Peyrin-Biroulet: Lorraine University

Drug Safety, 2021, vol. 44, issue 6, No 4, 645-660

Abstract: Abstract Introduction Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen. Objective The objective of this systematic review was to investigate the safety profile of S1P modulators in patients with multiple sclerosis, ulcerative colitis, Crohn’s disease, psoriasis, and systemic lupus erythematosus. Methods We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1 January, 1990 through 1 April, 2020. We also performed a manual review of conference databases from 2017 through 2020. The primary outcome was the occurrence of adverse events and serious adverse events. We also estimated the occurrence of serious infections, herpes zoster infection, malignancy, bradycardia, atrio-ventricular block, and macular edema. We performed a meta-analysis of controlled studies to assess the risks of such events. Results We identified 3843 citations; of these, 26 studies were finally included, comprising 9604 patients who were exposed to a sphingosine-1-phosphate modulator. A meta-analysis of randomized controlled trials showed an increased risk in herpes zoster infection [risk ratio, 1.75 (95% confidence interval 1.09–2.80)], bradycardia [2.64 (1.77–3.96)], and atrio-ventricular block [1.73 (1.03–2.91)] among subjects exposed to sphingosine-1-phosphate modulators as compared with a placebo or an active comparator. Conclusions We found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators. Clinical Trial Registration PROSPERO CRD42020172575.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-021-01057-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:6:d:10.1007_s40264-021-01057-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-021-01057-z

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().